Aurora Spine Corporation (TSXV: ASG | OTCQB: ASAPF) announced on October 22, 2026, that the 12-month results of its REFINE study have been published in the International Journal of Spine Surgery, with the article made available online on October 9, 2026. The peer-reviewed publication provides prospective, multicenter clinical evidence for the company's ZIP™ MIS Interlaminar Fusion System. The disclosure represents a meaningful step in Aurora Spine's effort to build a published clinical evidence base supporting the ZIP™ platform, a development investors in the spinal implant space may be watching closely.

Key Points

  • Aurora Spine Corporation (TSXV: ASG | OTCQB: ASAPF) is a Carlsbad, California-based developer of minimally invasive spinal implants and interventional pain management technologies.
  • The REFINE study's 12-month results were published in the International Journal of Spine Surgery (DOI: 10.14444/8969), available online as of October 9, 2026.
  • The study was a prospective, observational, open-label, nonrandomized, multicenter evaluation of the ZIP™ MIS Interlaminar Fusion System in patients with symptomatic neurogenic claudication.
  • Investors may be watching how this peer-reviewed evidence base influences clinician adoption discussions for the ZIP™ platform.

REFINE Study Design and Patient Population for the ZIP™ System

The REFINE study evaluated Aurora Spine's ZIP™ MIS Interlaminar Fusion System in patients with symptomatic neurogenic claudication associated with lumbar spinal stenosis in the presence of degenerative disc disease. The research was structured as a prospective, observational, open-label, nonrandomized, multicenter study, with participating investigators drawn from both spine surgery and interventional pain management specialties. This dual-specialty involvement, the release states, was intended to bring complementary clinical perspectives to the evaluation of interspinous stabilization as a treatment option.

Publication Adds Prospective Multicenter Evidence for Interspinous Stabilization

The published article is titled "A Prospective, Observational, Open-Label, Nonrandomized, Multicenter Study Measuring Functional Outcomes in a Novel Interspinous Stabilization Device in Patients With Low Back Pain: 12-Month Results for the REFINE Study." According to the announcement, the publication makes the study's 12-month findings available to clinicians evaluating interspinous stabilization and is intended to support patient selection and treatment planning discussions. The release notes that a Contract Research Organization supported the conduct of the study.

Aurora Spine's Commercial and Development Rationale for the ZIP™ Platform

Aurora Spine's Chief Commercial Officer, as quoted in the release, stated that physicians and healthcare partners seek published clinical evidence when evaluating a technology, and that the REFINE publication is intended to support those conversations. The company's Chief Technology Officer noted that prospective clinical follow-up helps evaluate how the ZIP™ technology performs in practice and informs future research and product development directions. The immediate share price impact was not clear from available public information.